Why Keros Therapeutics, Inc.’s (KROS) Stock Is Down 5.39%
As of Friday, August 14, Keros Therapeutics, Inc.’s KROS share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Commentary & Analysis
Why Keros Therapeutics, Inc.’s (KROS) Stock Is Down 6.44%
As of Friday, July 10, Keros Therapeutics, Inc.’s KROS share price has dipped by 6.44%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
3 Undervalued Biotechnology Stocks for Monday, June 15
Discover the top 3 undervalued Biotechnology stocks for Monday, June 15 based on AAII’s Stock Grades.Michael Rose
Why Keros Therapeutics, Inc.’s (KROS) Stock Is Up 5.05%
As of Wednesday, May 20, Keros Therapeutics, Inc.’s KROS share price has surged by 5.05%, which has investors questioning if this is right time to sell.Michael Rose
Why Keros Therapeutics, Inc.’s (KROS) Stock Is Down 11.26%
As of Thursday, May 14, Keros Therapeutics, Inc.’s KROS share price has dipped by 11.26%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | KROS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $218.7 | $292.6 | 28% |
|
| Shares Out (Mil) | 19.8 | 54.4 | 30% |
|
| Institutional Ownership | 96.7% | 93.2% | 71% |
|
| Float (Mil) | 17.8 | 40.2 | 27% |
|
| Beta | 1.01 | 0.94 | 62% |
|
| Avg Daily Volume (000s) | 201 | 544 | 44% |
|
| Price Change (52-week) |
(22.5%) | 59.7% | 27% |
|
| Growth | KROS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 31.4% | (10.1%) | 86% |
|
| EPS (5yr) | 22.7% | 16.0% | 72 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (19.5%) | (15.6%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 6 | 6 | |
| Current EPS | ($0.788) | ($5.142) | ($6.613) | |
| Month Ago EPS | ($1.298) | ($5.186) | ($5.593) | |
| # Rev Up | 0 | 2 | 1 | |
| # Rev Down | 4 | 1 | 1 | |
| Three Months Ago EPS | ($1.345) | ($5.228) | ($6.222) | |
| Year/Year Chg | (45.7%) | (323.6%) | (355.0%) | |
| Financials | KROS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $15 | $37 | 11% |
|
| Net Income (TTM) (Mil) | ($83) | ($43) | 13% |
|
| EPS (TTM) | ($3.105) | ($1.400) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($48) | ($31) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($433) | $2 | 6% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | ($39) | $164 | 1% |
|
| Valuation | KROS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.83 | 2.83 | 16% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | KROS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (388.6%) | 64.2% | 1% |
|
| Net Margin | (553.9%) | (75.9%) | 1% |
|
| ROA | (15.9%) | (47.5%) | 22% |
|
| ROE | (17.2%) | (55.0%) | 24% |
|
| Liabilities to Assets | 8.8% | 29.6% | 5% |
|
| F-Score | 4 | 3 | 33% |
|
Keros Therapeutics, Inc. did not pass any screens on 8/21/2026.
